Core Viewpoint - HaiXi New Drug has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International and CMB International as joint sponsors [1] Group 1: Company Overview - The company employs a "dual-track model" that includes both generic drugs and innovative drugs under development [1] - It has received NMPA approval for 14 generic drugs and has four innovative drugs in development, including a potential first-in-class oncology drug and a potential first oral drug for wAMD/DME/RVO [1] Group 2: Market Focus - The commercial product portfolio primarily targets diseases in the digestive system, cardiovascular system, endocrine system, nervous system, and inflammatory diseases, which collectively account for over 25% of China's total pharmaceutical sales in 2023 [1] - The company's main customers are state-owned pharmaceutical distribution companies, pharmacies, and retailers [1]
海西新药递表港交所 联席保荐人为华泰国际和招银国际
Zheng Quan Shi Bao Wang·2025-08-07 00:11